Sex differences in glutamate receptor gene expression in major depression and suicide

[1]  P. Pavlidis,et al.  miR-1202: A Primate Specific and Brain Enriched miRNA Involved in Major Depression and Antidepressant Treatment , 2014, Nature Medicine.

[2]  P. Zhong,et al.  Estrogen protects against the detrimental effects of repeated stress on glutamatergic transmission and cognition , 2014, Molecular Psychiatry.

[3]  N. Kalin,et al.  Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months. , 2013, JAMA psychiatry.

[4]  G. Hardingham,et al.  Influence of GluN2 subunit identity on NMDA receptor function , 2013, Neuropharmacology.

[5]  Chen Zhang,et al.  A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression , 2013, Psychopharmacology.

[6]  D. Wasserman,et al.  Glutamatergic GRIN2B and polyaminergic ODC1 genes in suicide attempts: associations and gene–environment interactions with childhood/adolescent physical assault , 2013, Molecular Psychiatry.

[7]  M. Austin,et al.  Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  Qiang Zhou,et al.  NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease , 2013, Nature Reviews Neuroscience.

[9]  K. Hashimoto,et al.  Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[10]  A C Heath,et al.  Multi-locus genome-wide association analysis supports the role of glutamatergic synaptic transmission in the etiology of major depressive disorder , 2012, Translational psychiatry.

[11]  P. Schofield,et al.  Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia , 2012, Molecular Psychiatry.

[12]  G. Rajkowska,et al.  Decreased Expression of Synapse-Related Genes and Loss of Synapses in Major Depressive Disorder , 2012, Nature Medicine.

[13]  A. Serretti,et al.  Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder , 2012, European Archives of Psychiatry and Clinical Neuroscience.

[14]  D. Swaab,et al.  Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients. , 2012, Journal of affective disorders.

[15]  C. Bethea,et al.  Ovarian steroids increase glutamatergic related gene expression in serotonin neurons of macaques , 2012, Molecular and Cellular Neuroscience.

[16]  B. Dean,et al.  AMPA receptor expression is increased post-mortem samples of the anterior cingulate from subjects with major depressive disorder. , 2012, Journal of affective disorders.

[17]  G. Sanacora,et al.  Towards a glutamate hypothesis of depression An emerging frontier of neuropsychopharmacology for mood disorders , 2012, Neuropharmacology.

[18]  R. Duman,et al.  Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents , 2012, Trends in Neurosciences.

[19]  Manfred Schneider,et al.  Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression , 2011, Journal of neurogenetics.

[20]  S. Chaki,et al.  Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression , 2011, Behavioural Brain Research.

[21]  Vahram Haroutunian,et al.  Glutamatergic Gene Expression Is Specifically Reduced in Thalamocortical Projecting Relay Neurons in Schizophrenia , 2011, Biological Psychiatry.

[22]  J. Jonides,et al.  Depression, rumination and the default network. , 2011, Social cognitive and affective neuroscience.

[23]  V. Treyer,et al.  Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. , 2011, The American journal of psychiatry.

[24]  C. Mulle,et al.  Kainate receptors coming of age: milestones of two decades of research , 2011, Trends in Neurosciences.

[25]  J. Kleinman,et al.  Psychiatric Brain Banking: Three Perspectives on Current Trends and Future Directions , 2011, Biological Psychiatry.

[26]  G. Rajkowska,et al.  Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. , 2010, The international journal of neuropsychopharmacology.

[27]  G. Hasler,et al.  Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[28]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[29]  Ian J. Deary,et al.  Association of Existing and New Candidate Genes for Anxiety, Depression and Personality Traits in Older People , 2010, Behavior genetics.

[30]  M. Ikeda,et al.  Association analysis of Group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[31]  A. Minelli,et al.  An Association of GRIK3 Ser310Ala Functional Polymorphism with Personality Traits , 2009, Neuropsychobiology.

[32]  C. Stockmeier,et al.  Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[33]  G. Collingridge,et al.  Kainate receptors: Pharmacology, function and therapeutic potential , 2009, Neuropharmacology.

[34]  D. Lodge.  The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature , 2009, Neuropharmacology.

[35]  M. Krams,et al.  An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder , 2008, Journal of clinical psychopharmacology.

[36]  M. Burset,et al.  Multiplex preamplification of specific cDNA targets prior to gene expression analysis by TaqMan Arrays , 2008, BMC Research Notes.

[37]  C. Zarate,et al.  The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects , 2007, Current psychiatry reports.

[38]  S. Hemby,et al.  Elevated GRIA1 mRNA expression in Layer II/III and V pyramidal cells of the DLPFC in schizophrenia , 2007, Schizophrenia Research.

[39]  K. Beck,et al.  Chronic Stress and Neural Function: Accounting for Sex and Age , 2007, Journal of neuroendocrinology.

[40]  G. Szabó,et al.  Glutamatergic or GABAergic neuron-specific, long-term expression in neocortical neurons from helper virus-free HSV-1 vectors containing the phosphate-activated glutaminase, vesicular glutamate transporter-1, or glutamic acid decarboxylase promoter , 2007, Brain Research.

[41]  H. Manji,et al.  The Anticonvulsants Lamotrigine, Riluzole, and Valproate Differentially Regulate AMPA Receptor Membrane Localization: Relationship to Clinical Effects in Mood Disorders , 2007, Neuropsychopharmacology.

[42]  J. Krystal,et al.  Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms , 2007, Biological Psychiatry.

[43]  H. Schiffer,et al.  Association of the human kainate receptor GluR7 gene (GRIK3) with recurrent major depressive disorder , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[44]  Xia Li,et al.  Metabotropic Glutamate 5 Receptor Antagonism Is Associated with Antidepressant-Like Effects in Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[45]  J. Kleinman,et al.  Critical Factors in Gene Expression in Postmortem Human Brain: Focus on Studies in Schizophrenia , 2006, Biological Psychiatry.

[46]  E. Lambe,et al.  Hallucinogen-Induced UP States in the Brain Slice of Rat Prefrontal Cortex: Role of Glutamate Spillover and NR2B-NMDA Receptors , 2006, Neuropsychopharmacology.

[47]  Carlos A. Zarate,et al.  Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder , 2006, Biological Psychiatry.

[48]  Olga V. Demler,et al.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[49]  T. Bredy,et al.  Epigenetic Programming of Stress Responses through Variations in Maternal Care , 2004, Annals of the New York Academy of Sciences.

[50]  S. Nakanishi,et al.  MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity , 2004, Neuropharmacology.

[51]  J. Krystal,et al.  Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder , 2003, Psychopharmacology.

[52]  Abraham Weizman,et al.  Amantadine as augmentation therapy in the management of treatment-resistant depression , 2003, International clinical psychopharmacology.

[53]  K. Shibuki,et al.  Differential dependence of LTD on glutamate receptors in the auditory cortical synapses of cortical and thalamic inputs. , 2002, Journal of neurophysiology.

[54]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[55]  C. Woolley,et al.  Estradiol Increases the Sensitivity of Hippocampal CA1 Pyramidal Cells to NMDA Receptor-Mediated Synaptic Input: Correlation with Dendritic Spine Density , 1997, The Journal of Neuroscience.

[56]  D. Wyllie,et al.  Single-channel currents from recombinant NM DANRla /NR2D receptors expressed in Xenopus oocytes , 1996, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[57]  T. Kuner,et al.  Multiple Structural Elements Determine Subunit Specificity of Mg2+ Block in NMDA Receptor Channels , 1996, The Journal of Neuroscience.

[58]  R. Schneggenburger,et al.  Simultaneous measurement of Ca2+ influx and reversal potentials in recombinant N-methyl-D-aspartate receptor channels. , 1996, Biophysical journal.

[59]  P S Goldman-Rakic,et al.  Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. , 1995, Cerebral cortex.

[60]  D. Brent,et al.  Suicide and Aging I: Patterns of Psychiatric Diagnosis , 1995, International Psychogeriatrics.

[61]  G. Nowak,et al.  Alterations in the N-methyl-d-asparatate (NMDA) receptor complex in the frontal cortex of suicide victims , 1995, Brain Research.

[62]  C. Katona,et al.  NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides , 1993, Brain Research.

[63]  P. Stern,et al.  Single-channel conductances of NMDA receptors expressed from cloned cDNAs: comparison with native receptors , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[64]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[65]  J. Ballenger.  Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort , 2009 .

[66]  D. Charney,et al.  Intravenous ketamine for treatment-resistant major depressive disorder , 2008 .

[67]  M. Oquendo,et al.  Sex differences in clinical predictors of suicidal acts after major depression: a prospective study. , 2007, The American journal of psychiatry.

[68]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[69]  D. Luckenbaugh,et al.  An open-label trial of riluzole in patients with treatment-resistant major depression. , 2004, The American journal of psychiatry.